Comparative neurochemical profile of 3,4-methylenedioxymethamphetamine and its metabolite alpha-methyldopamine on key targets of MDMA neurotoxicity

Neurochemistry International

Volumn 58, Issue 1, 2011, Pages 92-101

  Escubedo, E ^a   Abad, S ^a   Torres, I ^a   Camarasa, J ^a   Pubill, D ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Dopamine transporter; Ecstasy; MDMA; Methyldopamine; Serotonin transporter

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALPHA METHYLDOPAMINE; DOPAMINE; NICOTINIC RECEPTOR; SEROTONIN TRANSPORTER;

ARTICLE; CELL VIABILITY; CYTOTOXICITY; MALE; NEUROCHEMISTRY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SYNAPTOSOME;

ANIMALS; CELL MEMBRANE; CELL SURVIVAL; COCAINE; DEOXYEPINEPHRINE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; MALE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROTOXICITY SYNDROMES; PAROXETINE; PC12 CELLS; PROTEIN CONFORMATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; SYNAPTOSOMES;

ANIMALIA; MEDA; MUS; RATTUS; RODENTIA;

EID: 78650414030     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2010.11.001     Document Type: Article

References (48)

1. T.T. Abraham, A.J. Barnes, R.H. Lowe, E.A. Kolbrich Spargo, G. Milman, S.O. Pirnay, D.A. Gorelick, R.S. Goodwin, and M.A. Huestis Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans J. Anal. Toxicol. 33 2009 439 446
2. A.M. Avila, M.I. Davila-Garcia, V.S. Ascarrunz, Y. Xiao, and K.J. Kellar Differential regulation of nicotinic acetylcholine receptors in PC12 cells by nicotine and nerve growth factor Mol. Pharmacol. 64 2003 974 986
3. D.J. Balfour, A.E. Wright, M.E. Benwell, and C.E. Birrell The putative role of extra-synaptic mesolimbic dopamine in the neurobiology of nicotine dependence Behav. Brain Res. 113 2000 73 83
4. J. Camarasa, J.M. Marimón, T. Rodrigo, E. Escubedo, and D. Pubill Memantine prevents the cognitive impairment induced by 3,4- methylenedioxymethamphetamine in rats Eur. J. Pharmacol. 589 2008 132 139
5. J. Camarero, V. Sanchez, E. O'Shea, A.R. Green, and M.I. Colado Studies, using in vivo microdialysis, on the effect of the dopamine uptake inhibitor GBR 12909 on 3,4-methylenedioxymethamphetamine ('ecstasy')-induced dopamine release and free radical formation in the mouse striatum J. Neurochem. 81 2002 961 972
6. J.P. Capela, C. Macedo, P.S. Branco, L.M. Ferreira, A.M. Lobo, E. Fernandes, F. Remião, M.L. Bastos, U. Dirnagl, A. Meisel, and F. Carvalho Neurotoxicity mechanisms of thioether ecstasy metabolites Neuroscience 146 2007 1743 1757
7. J.P. Capela, A. Meisel, A.R. Abreu, P.S. Branco, L.M. Ferreira, A.M. Lobo, F. Remião, M.L. Bastos, and F. Carvalho Neurotoxicity of Ecstasy metabolites in rat cortical neurons, and influence of hyperthermia J. Pharmacol. Exp. Ther. 316 2006 53 61
8. N. Chen, and M.E. Reith Interaction between dopamine and its transporter: role of intracellular sodium ions and membrane potential J. Neurochem. 89 2004 750 765
9. C. Chipana, J. Camarasa, D. Pubill, and E. Escubedo Protection against MDMA-induced dopaminergic neurotoxicity in mice by methyllycaconitine: involvement of nicotinic receptors Neuropharmacology 51 2006 885 895
10. C. Chipana, S. García-Ratés, J. Camarasa, D. Pubill, and E. Escubedo Different oxidative profile and nicotinic receptor interaction of amphetamine and 3,4-methylenedioxy-methamphetamine Neurochem. Int. 52 2008 401 410
11. C. Chipana, I. Torres, J. Camarasa, D. Pubill, and E. Escubedo Memantine protects against amphetamine derivatives-induced neurotoxic damage in rodents Neuropharmacology 54 2008 1254 1263
12. M.I. Colado, J.L. Williams, and A.R. Green The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype Br. J. Pharmacol. 115 1995 1281 1289
13. 3H]methyllycaconitine: a new radioligand for labelling alpha7-type neuronal nicotinic acetylcholine receptors Neuropharmacology 38 1999 679 690
14. R. de la Torre, M. Farré, P.N. Roset, C.H. Lopez, M. Mas, J. Ortuño, E. Menoyo, N. Pizarro, J. Segura, and J. Cami Pharmacology of MDMA in humans Ann. N.Y. Acad. Sci. 914 2000 225 237
15. R. de la Torre, M. Farre, P.N. Roset, N. Pizarro, S. Abanades, M. Segura, J. Segura, and J. Cami Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition Ther. Drug. Monit. 26 2004 137 144
16. E. Escubedo, J. Camarasa, C. Chipana, S. García-Ratés, and D. Pubill Involvement of nicotinic receptors in methamphetamine and MDMA induced neurotoxicity. Pharmacologial implications Int. Rev. Neurobiol. 88 2009 121 166
17. E. Escubedo, C. Chipana, M. Pérez-Sánchez, J. Camarasa, and D. Pubill Methyllycaconitine prevents methamphetamine-induced effects in mouse striatum: involvement of alpha7 nicotinic receptors J. Pharmacol. Exp. Ther. 315 2005 658 667
18. B. Esteban, E. O'Shea, J. Camarero, V. Sanchez, A.R. Green, and M.I. Colado 3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose Psychopharmacology (Berl.) 154 2001 251 260
19. S. García-Ratés, J. Camarasa, E. Escubedo, and D. Pubill Methamphetamine and 3,4-methylenedioxymethamphetamine interact with central nicotinic receptors and induce their up-regulation Toxicol. Appl. Pharmacol. 223 2007 195 205
20. M.E. Gnegy, H. Khoshbouei, K.A. Berg, J.A. Javitch, W.P. Clarke, M. Zhang, and A. Galli Intracellular Ca2+ regulates amphetamine-induced dopamine efflux and currents mediated by the human dopamine transporter Mol. Pharmacol. 66 2004 137 143
21. B. Goñi-Allo, E. Puerta, B.O. Mathúna, I. Hervias, B. Lasheras, R. de la Torre, and N. Aguirre On the role of tyrosine and peripheral metabolism in 3,4-methylenedioxymethamphetamine-induced serotonin neurotoxicity in rats Neuropharmacology 54 2008 885 900
22. A.R. Green, A.O. Mechan, J.M. Elliott, E. O'Shea, and M.I. Colado The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") Pharmacol. Rev. 55 2003 463 508
23. H. Guang, and G. Du High-throughput screening for monoamine oxidase-A and monoamine oxidase-B inhibitors using one-step fluorescence assay Acta Pharmacol. Sin. 27 2006 760 766
24. G.A. Gudelsky, and J.F. Nash Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions J. Neurochem. 66 1996 243 249
25. J.P. Hansen, E.L. Riddle, V. Sandoval, J.M. Brown, J.W. Gibb, G.R. Hanson, and A.E. Fleckenstein Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity J. Pharmacol. Exp. Ther. 300 2002 1093 1100
26. 3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain Mol. Pharmacol. 48 1995 280 287
27. S.L. Hrometz, A.W. Brown, D.E. Nichols, and J.E. Sprague 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy)-mediated production of hydrogen peroxide in an in vitro model: the role of dopamine, the serotonin-reuptake transporter, and monoamine oxidase-B Neurosci. Lett. 367 2004 56 59
28. M.M. Iravani, D. Asari, J. Patel, W.J. Wieczorek, and Z.L. Kruk Direct effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin or dopamine release and uptake in the caudate putamen, nucleus accumbens, substantia nigra pars reticulata, and the dorsal raphé nucleus slices Synapse 36 2000 275 285
29. S. Jayanthi, B. Ladenheim, A.M. Andrews, and J.L. Cadet Overexpression of human copper/zinc superoxide dismutase in transgenic mice attenuates oxidative stress caused by methylenedioxymethamphetamine (Ecstasy) Neuroscience 91 1999 1379 1387
30. A. Jiménez, E.G. Jorda, E. Verdaguer, D. Pubill, F.X. Sureda, A.M. Canudas, E. Escubedo, J. Camarasa, A. Camins, and M. Pallas Neurotoxicity of amphetamine derivatives is mediated by caspase pathway activation in rat cerebellar granule cells Toxicol. Appl. Pharmacol. 196 2004 223 234
31. M. Johnson, I. Elayan, G.R. Hanson, R.L. Foltz, J.W. Gibb, and H.K. Lim Effects of 3,4-dihydroxymethamphetamine and 2,4,5-trihydroxymethamphetamine, two metabolites of 3,4-methylenedioxymethamphetamine, on central serotonergic and dopaminergic systems J. Pharmacol. Exp. Ther. 261 1992 447 453
32. D.C. Jones, C. Duvauchelle, A. Ikegami, C.M. Olsen, S.S. Lau, R. de la Torre, and T.J. Monks Serotonergic neurotoxic metabolites of ecstasy identified in rat brain J. Pharmacol. Exp. Ther. 313 2005 422 431
33. D.C. Jones, S.S. Lau, and T.J. Monks Thioether metabolites of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine inhibit human serotonin transporter (hSERT) function and simultaneously stimulate dopamine uptake into hSERT-expressing SK-N-MC cells J. Pharmacol. Exp. Ther. 311 2004 298 306
34. S. Koch, and M.P. Galloway MDMA induced dopamine release in vivo: role of endogenous serotonin J. Neural Transm. 104 1997 135 146
35. E.T. Leonardi, and E.C. Azmitia MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac) Neuropsychopharmacology 10 1994 231 238
36. U. McCann, and G.A. Ricaurte Major metabolites of (±)3,4- methylenedioxyamphetamine (MDA) do not mediate its toxic effects on brain serotonin neurons Brain Res. 545 1991 279 282
37. T.J. Monks, D.C. Jones, F. Bai, and S.S. Lau The role of metabolism in 3,4-(+)-methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) toxicity Ther. Drug Monit. 26 2004 132 136
38. M. Mueller, J. Yuan, A. Felim, A. Neudörffer, F.T. Peters, H.H. Maurer, U.D. McCann, M. Largeron, and G.A. Ricaurte Further studies on the role of metabolites in (+/-)-3,4-methylenedioxymethamphetamine-induced serotonergic neurotoxicity Drug Metab. Dispos. 37 2009 2079 2086
39. S.U. Park, J.V. Ferrer, J.A. Javitch, and D.M. Kuhn Peroxynitrite inactivates the human dopamine transporter by modification of cysteine 342: potential mechanism of neurotoxicity in dopamine neurons J. Neurosci. 22 2002 4399 4405
40. D. Pubill, A.M. Canudas, M. Palls, A. Camins, J. Camarasa, and E. Escubedo Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity Naunyn Schmiedeberg's Arch. Pharmacol. 367 2003 490 499
41. D. Pubill, C. Chipana, A. Camins, M. Pallas, J. Camarasa, and E. Escubedo Free radical production induced by methamphetamine in rat striatal synaptosomes Toxicol. Appl. Pharmacol. 204 2005 57 68
42. S.N. Saldana, and E.L. Barker Temperature and 3,4- methylenedioxymethamphetamine alter human serotonin transporter-mediated dopamine uptake Neurosci. Lett. 354 2004 209 212
43. R.H. Schwartz, and N.S. Miller MDMA (ecstasy) and the rave: a review Pediatrics 100 1997 705 708
44. J.E. Sprague, S.L. Everman, and D.E. Nichols An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine Neurotoxicology 19 1998 427 441
45. J. Sprague, and D.E. Nichols The monoamine oxidase-B inhibitor l-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits J. Pharmacol. Exp. Ther. 273 1995 667 673
46. J.E. Sprague, and D.E. Nichols Neurotoxicity of MDMA (ecstasy): beyond metabolism Trends Pharmacol. Sci. 26 2005 59 60
47. E. Verdaguer, E. Garcia-Jord, A. Jimenez, A. Stranges, F.X. Sureda, A.M. Canudas, E. Escubedo, J. Camarasa, M. Palls, and A. Camins Kainic acid induced neuronal cell death in cerebellar granule cells is not prevented by caspase inhibitors Br. J. Pharmacol. 135 2002 1297 1307
48. J. Zhen, N. Chen, and M.E. Reith Differences in interactions with the dopamine transporter as revealed by diminishment of Na(+) gradient and membrane potential: dopamine versus other substrates Neuropharmacology 49 2005 769 779